Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,
such as rituximab, can block cancer growth in different ways. Some block the ability of
cancer cells to grow and spread. Others find cancer cells and help kill them or carry
cancer-killing substances to them. Giving rituximab together with combination chemotherapy
may kill more cancer cells.
PURPOSE: This clinical trial is studying the side effects and best ways to give combination
chemotherapy together with rituximab in treating patients with newly diagnosed primary CNS
lymphoma.